827 860
[15] Erovic BM, Woegerbauer M, Pammer J, Selzer E, Grasl MC, Thurnher
D. Strong evidence for up-regulation of cyclooxygenase-1 in head
and neck cancer. Eur J Clin Invest 2008;38:61–6.
http://dx.doi.org/ 10.1111/j.1365-2362.2007.01896.x.
[16] Yoshimura N, Sano H, Okamoto M, et al. Expression of cyclooxy-
genase-1 and -2 in human breast cancer. Surg Today 2003;33:805–
11.
http://dx.doi.org/10.1007/s00595-003-2606-3.
[17]
Labelle M, Begum S, Hynes RO. Platelets guide the formation of early metastatic niches. Proc Natl Acad Sci U S A 2014;111: E3053–61.
[18] Li R, Ren M, Chen N, et al. Presence of intratumoral platelets
is associated with tumor vessel structure and metastasis. BMC
Cancer 2014;14:167–77.
http://dx.doi.org/10.1186/1471-2407- 14-167 .[19] Jahn J, Giovannucci E, Stampfer M. The high prevalence of undiag-
nosed prostate cancer at autopsy: implications for epidemiology and
treatment of prostate cancer in the prostate-specific antigen-era. Int J
Cancer 2015;137:2795–802.
http://dx.doi.org/10.1002/ijc.29408.
[20] Klotz L, Vesprini D, Sethukavalan P, et al. Long-term follow-up of a
large active surveillance cohort of patients with prostate cancer.
J Clin Oncol 2014;33:272–7.
http://dx.doi.org/10.1200/JCO.2014. 55.1192 .[21]
Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long- term supplementation with beta carotene on the incidence of ma- lignant neoplasms and cardiovascular disease. N Engl J Med 1996; 334:1145–9.[22]
Charlson M, Pompei P, Ales K, MacKenzie C. A new method of classifying prognostic comorbidity in longitudinal studies: devel- opment and validation. J Chronic Dis 1987;40:373–83.
[23] Simmons MN, Stephenson AJ, Klein EA. Natural history of biochem-
ical recurrence after radical prostatectomy: risk assessment for
secondary therapy. Eur Urol 2007;51:1175–84
. http://dx.doi.org/ 10.1016/j.eururo.2007.01.015 .[24] Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh
PC. Natural history of progression after PSA elevation following
radical prostatectomy. JAMA 1999;281:1591–7
. http://dx.doi.org/ 10.1097/00005392-199910000-00103.
[25]
TornblomM, Eriksson H, Franzen S, et al. Lead time associated with screening for prostate cancer. Int J Cancer 2004;108:122–9.
[26] Jacobs EJ, Newton CC, Stevens VL, Campbell PT, Freedland SJ,
Gapstur SM. Daily aspirin use and prostate cancer-specific mortali-
ty in a large cohort of men with nonmetastatic prostate cancer.
J Clin Oncol 2014;32:3716–22
. http://dx.doi.org/10.1200/JCO.2013. 54.8875 .[27] Choe KS, Cowan JE, Chan JM, Carroll PR, D’Amico AV, Liauw SL.
Aspirin use and the risk of prostate cancer mortality in men treated
with prostatectomy or radiotherapy. J Clin Oncol 2012;30:3540–4.
http://dx.doi.org/10.1200/JCO.2011.41.0308.
[28] Dhillon PK, Kenfield SA, Stampfer MJ, Giovannucci EL, Chan JM.
Aspirin use after a prostate cancer diagnosis and cancer survival in a
prospective cohort. Cancer Prev Res 2012;5:1223–8
. http://dx.doi. org/10.1158/1940-6207.CAPR-12-0171.
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 8 2 1 – 8 2 7
827